Connect® Myeloid Disease Registry

Stopped early

Conditions studied: Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

In brief

The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.

Key facts

Study ID: NCT01688011
Run by: Celgene
People needed: 2013
Starts: 2013-12-12
Expected to finish: 2024-10-18
Last updated by the study team: 2025-07-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients must be able to provide written informed consent form (ICF)
Must be willing and able to complete baseline and follow-up HRQoL instruments, for which patients must be proficient in either English or Spanish
AML patients must be at least 55 years of age at the time of informed consent.
MF, ICUS, and MDS patients must be at least 18 years of age at the time of informed consent.
Newly diagnosed Idiopathic Cytopenias of Undetermined Significance (ICUS), Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) patients:
Newly diagnosed primary or secondary disease. To be considered "newly diagnosed", a patient's confirmed diagnosis must be made no more than 60 days prior to the date of consent signature. (An additional 5-day window [i.e., up to 65 days prior to the date of ICF signature] may be allowed in special circumstance upon sponsor approval)
Cohort assignment confirmed by central eligibility review. Cohort assignment must also be confirmed by the site.
Myelofibrosis (MF) patients:
Patients who initiated their first active systemic treatment for MF and/or MF-related cytopenias within 90 days prior to the date of consent signature. This cohort allows the enrollment of subjects with a diagnosis of Myelodysplastic/Myeloproliferative overlap syndromes (MDS/MPN overlap syndrome).
Cohort assignment is confirmed by the site. Central eligibility review is not required.
Treated Lower-Risk Myelodysplastic Syndromes (LR-MDS) patients:
Patients who have initiated first active treatment regimen containing at least one non-ESA therapy, within 90 days prior to ICF
Cohort assignment is confirmed by site. Central eligibility review is not required.
Luspatercept treated patients:
Patient must have been at least 18 years of age at the start of luspatercept.
Among LR-MDS patients, patient must have initiated luspatercept on or after September 1, 2023, must be ESA-naïve and luspatercept must be the first active treatment (as monotherapy or part of a treatment regimen) for their disease.
Among all other myeloid malignancies, there is no date restriction for initiation of luspatercept .Patient may have received prior treatment for their disease.
Patient must have at least 3 months of follow-up from start of luspatercept treatment at the participating site.

You may not qualify if…

Suspected or proven acute promyelocytic leukemia (APL) (FAB M3 or WHO 2008) based on morphology, immunophenotype, molecular assay or karyotype
Currently enrolled in any interventional clinical trial where the patient is being treated with an investigational product that cannot be identified.
Idiopathic Cytopenias of Undetermined Significance (ICUS), Myelodysplastic Syndromes (MDS) patients who received or are receiving active (disease modifying) therapy for the treatment of MDS prior to the date of informed consent.
Acute Myeloid Leukemia (AML) patients who initiated active (disease modifying treatment for AML more than 2 weeks prior to the date of consent.
Myelofibrosis (MF) and Myelodysplastic/Myeloproliferative (MDS/MPN) overlap syndrome patients with suspected juvenile myelomonocytic leukemia (JMML).
Luspatercept treated patients:
Patient must not be currently or previously enrolled in the Connect Myeloid Registry.
Patient must not have received luspatercept as part of a clinical trial.

Where it is running

Arizona Oncology — Phoenix, Arizona, United States
The University of Arizona Cancer Center — Tucson, Arizona, United States
Local Institution - 1273 — Tucson, Arizona, United States
Highlands Oncology Group — Fayetteville, Arkansas, United States
Clopton Clinic of Jonesboro, Inc. — Jonesboro, Arkansas, United States
NEABC- Fowler Family Center for Cancer Care — Jonesboro, Arkansas, United States
Local Institution - 1161 — Jonesboro, Arkansas, United States
Comprehensive Blood & Cancer Center — Bakersfield, California, United States
Alta Bates Summit Comprehensive Cancer — Berkeley, California, United States
Sutter East Bay Hospitals (dba Jordan Research and Education Institute - REDI) — Berkeley, California, United States
John Muir Clinical Research Center — Concord, California, United States
VA Central California Health Care System — Fresno, California, United States
UCSD Moores Cancer Center — La Jolla, California, United States
Pacific Cancer Care — Monterey, California, United States
Local Institution - 1016 — San Diego, California, United States
Local Institution - 1027 — Santa Rosa, California, United States
St. Joseph's Regional Cancer Center — Stockton, California, United States
Saint Joseph Hospital, Cancer Centers of Colorado — Denver, Colorado, United States
Regional Cancer Care Associates — Manchester, Connecticut, United States
Bennett Cancer Center Stamford Hospital — Stamford, Connecticut, United States
Delaware Clinical and Laboratory Physicians — Christiana, Delaware, United States
University Cancer Institute — Boynton Beach, Florida, United States
Halifax Health Center for Oncology — Daytona Beach, Florida, United States
Holy Cross Hospital — Fort Lauderdale, Florida, United States
DCH Health System (Lewis and Faye Manderson Cancer Center) — Tuscaloosa, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.